News from Anthera Pharmaceuticals, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 23, 2010, 09:00 ET Anthera Enrolls First Patients in Pivotal Varespladib Phase 3 Clinical Study

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...


Jun 10, 2010, 14:42 ET Anthera Pharmaceuticals Updates Its Lupus Scientific Advisory Board

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing therapeutics to treat serious diseases associated with...


Jun 03, 2010, 17:00 ET Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing therapeutics to treat serious diseases associated with...


May 06, 2010, 16:15 ET Anthera Issues First Quarter 2010 Financial Report

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today issued its first quarter 2010 financial report. Financial Results Total operating expenses...


May 03, 2010, 08:00 ET Anthera Pharmaceuticals Announces Additional Data from FRANCIS Study

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...


Apr 28, 2010, 17:00 ET Anthera Announces First Quarter 2010 Financial Report and Conference Call

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...


Apr 26, 2010, 17:00 ET Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...


Apr 06, 2010, 17:00 ET Anthera Pharmaceuticals Announces Closing of Underwriters' Exercise of Over-Allotment Option in Connection With Its Initial Public Offering

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...


Mar 23, 2010, 17:00 ET Anthera Pharmaceuticals Welcomes Georgina Kilfoil as Senior Vice President of Product Development and Clinical Operations

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...


Mar 04, 2010, 16:30 ET Anthera Pharmaceuticals Completes Initial Public Offering

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...


Feb 08, 2010, 07:00 ET Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...


May 06, 2009, 07:00 ET Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

- Favorable results for secondary endpoints support outcomes benefit Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company...


Mar 24, 2009, 07:00 ET Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after...


Nov 11, 2008, 07:00 ET Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced new data on its lead...


Apr 17, 2008, 01:00 ET Anthera Presents Data on Varespladib at ATVB Meeting

SAN MATEO, Calif., April 17 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing...


Apr 16, 2008, 01:00 ET DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

SAN MATEO, Calif., April 16 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing...


Feb 07, 2008, 00:00 ET Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions

SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory...


Feb 05, 2008, 00:00 ET Anthera Pharmaceuticals Forms Scientific Advisory Board

SAN MATEO, Calif., Feb. 5 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held drug development company, announced today that it has...


Jan 31, 2008, 00:00 ET Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials

SAN MATEO, Calif., Jan. 31 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. today announced it has entered into manufacturing agreements with...


Jan 15, 2008, 00:00 ET Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial

SAN MATEO, Calif., Jan. 15 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported preliminary...